Civica Rx Aims to Disrupt Generic Insulin Market Pricing by 2024

Civica Rx Aims to Disrupt Generic Insulin Market Pricing by 2024. A hand holds an insulin pen.

Prices for several generic insulins in 2024 could be no more than $30 per vial and no more than $55 for a box of five pen cartridges — only a quarter of what they are today — if Civica Rx has its way. Pending federal approval, the nonprofit consortium of U.S. hospitals plans to manufacture and distribute the generics, continuing its mission to alleviate chronic shortages of inpatient drugs and reduce drug prices.

Civica’s effort is supported by its member hospitals, the Blue Cross Blue Shield Association and 12 independent BCBS organizations, insurers and philanthropies. With its development partner GeneSys Biologics, Civica will manufacture three generics: glargine, lispro and aspart, each of which will be available in vials and prefilled pens.

If the consortium gets needed Federal Drug Administration licensing approval following its clinical trials, it would begin selling the generics in 2024. The move would be particularly helpful to up to 25% of insulin users who sometimes ration their insulin or skip doses because of high costs, according to a 2019 study published in JAMA Internal Medicine.

Insulin has become inaccessible for many, causing debilitating and preventable illness, the Civica statement notes. This disproportionately impacts people with diabetes who are Native American, Hispanic or Black, because they are more likely to be underinsured or uninsured.

The insulins will be manufactured at Civica’s 140,000 square-foot plant being built in Petersburg, Va. The facility will have the capacity to produce a substantial amount of the insulin needed in the U.S., with additional space to increase production if needed.

AHA Center for Health Innovation logo

Related Resources

Case Studies
Public
Like many hospitals across the country, Cheyenne Regional Medical Center in Laramie County, Wyoming, was seeing the effects of the nationwide opioid crisis –…
Case Studies
Public
OSF HealthCare, based in Peoria, Illinois, launched OSF Innovation to “embrace change and take on the largest health care challenges.” The team assessed what…
AHA Center for Health Innovation Market Scan
In analyzing the current state of transformation, leaders from health systems, insurers, digital health companies and others at Modern Healthcare’s recent…
AHA Center for Health Innovation Market Scan
The Agency for Healthcare Research and Quality (AHRQ) recently issued a technical brief, “Evaluation of Mental Health Mobile Applications” to aid providers,…
AHA Center for Health Innovation Market Scan
Health care’s digital transformation has been hastened by many factors, not the least of which is competition from consumer-savvy retailers in the primary care…
AHA Center for Health Innovation Market Scan
Moxi is a four-foot-tall, 300-pound collaborative robot from Diligent Robotics. She comes equipped with a mechanical arm, gripping hand and mobility that…